The magical microbiome
By Brittany Niccum and Han Wei Now that we are past the holiday season and…
January 20, 2023 - 6 minutes
Microbiome: An Emerging Field with Growing Investments
The potential of the microbiome to be used for the development of promising therapeutics and diagnostic approaches has spurred a hype around this emerging field. Over the last decade, researchers have found correlations between the human microbiome and a number of diseases, including inflammatory bowel disease, diabetes, autoimmune diseases, cancer, depression, and many more. As the number of clinical trials grows, investor interest is increasing.
Read on to find out more about the flourishing microbiome field and how it shows promise for the treatment of a large variety of diseases.
Show More
Editor's Picks for Microbiome
- UK Startup Surfs Investment Wave in Microbiome with €18M Series A
- Microbiome Medicines Could Power Up CAR-T Cell Therapies
- Investing in the Microbiome in the Age of Covid-19 and Beyond
- The Missing Piece in the Microbiome Field
- No Guts, No Glory: How Microbiome Research is Changing Medicine
Beyond the Gut: An Atlas of the Human Microbiome
This report discusses the role of the gut and blood microbiomes in different diseases and how they can be used for biomarker discovery and for the development of therapeutics.
Go to ReportLatest Microbiome Articles
EverImmune launches trial for oncobiotic lung and kidney cancer drug candidate
EverImmune, a clinical-stage biotechnology company specialized in the development of live biotherapeutic products in the…
January 17, 2023 - 3 minutes
What’s in store for biotech in 2023?
Perhaps 2022 will best be remembered in the life science industry for the return of…
January 11, 2023 - 14 minutes
2023 Editorial Calendar updated
Each month here at Labiotech.eu, we produce a special newsletter. While still news-related, these special…
January 5, 2023 - 3 minutes
Biomica raises $20M to advance microbiome-based therapeutics pipeline
Biomica Ltd., a subsidiary of Evogene Ltd., has signed a definitive agreement for a $20…
December 21, 2022 - 2 minutes
Interview: why the recently approved fecal microbiome product is causing a rumble
The news last week of the FDA approving Ferring Pharmaceuticals' first fecal microbiome product, Rebyota,…
December 5, 2022 - 5 minutes
FDA’s approval of first fecal microbiota product, Rebyota, hailed an ‘enormous step forward’ for the field
The first fecal microbiota product, Rebyota, approved by the U.S. Food and Drug Administration (FDA)…
December 1, 2022 - 6 minutes
MaaT Pharma: leading the charge in microbiome therapeutics
The first generation of microbiome therapeutics is hitting its first approvals. Savita Bernal, chief business…
November 14, 2022 - 5 minutes
Persephone Biosciences studies the microbiome in baby poop
Disruption in the gut microbiome is linked to a wide range of health problems in…
October 28, 2022 - 6 minutes
Neobe Therapeutics breaks down tumor defenses with bacteria
Many cancer patients cannot benefit from cancer immunotherapy because their tumors are protected from the…
October 19, 2022 - 4 minutes
Clinical Microbiomics acquires MS-Omics
Clinical Microbiomics, a microbiome research company, has acquired MS-Omics, a metabolomics provider based in Denmark. …
October 17, 2022 - 2 minutes
Skin microbiome research could lead to new approaches for addressing organ damage after stem cell transplants
Skin microbiome research could lead to new approaches for addressing organ damage after stem cell…
October 13, 2022 - 3 minutes
